{
    "clinical_study": {
        "@rank": "151458", 
        "arm_group": [
            {
                "arm_group_label": "Part I: Dose Escalation, Combination", 
                "arm_group_type": "Experimental", 
                "description": "Three intratumoral administrations of VCN-01 oncolytic adenovirus every 21 days in combination with a fixed dose of Gemcitabine"
            }, 
            {
                "arm_group_label": "Part II: VCN-01, Single Agent", 
                "arm_group_type": "Experimental", 
                "description": "Three intratumoral administrations of VCN-01 oncolytic adenovirus every 21 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and tolerability of three intratumoral\n      injections of VCN-01, either administered alone or in combination with gemcitabine, in\n      patients with advanced pancreatic adenocarcinoma, and to determine the recommended phase II\n      dose of VCN-01 combined with gemcitabine."
        }, 
        "brief_title": "A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With or Without Gemcitabine in Patients With Advanced Pancreatic Cancer", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Locally Advanced Pancreatic Adenocarcinoma", 
            "Metastatic Pancreatic Adenocarcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study consists in two parts:\n\n        -  Part I is a dose escalation study to determine the safety and tolerability of three\n           intratumoral injections of VCN-01 in combination with a fixed dose of gemcitabine\n\n        -  Part II only intratumoral VCN-01 consisting of three intratumoral injections will be\n           administered"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male/Female patients aged 18 years or over\n\n          -  Patients must provide written informed consent\n\n          -  Life expectancy above 3 months\n\n          -  Patients willing to comply with treatment follow-up, and to accept a biopsy at day 22\n             after initiation of the treatment\n\n          -  Patients with histologically confirmed diagnosis of locally advanced unresectable\n             pancreatic adenocarcinoma (Stage III-TNM-Seventh Edition 2010) or metastatic\n             pancreatic adenocarcinoma (Stage IV-TNM-Seventh Edition 2010) with symptoms related\n             to the primary tumor.\n\n          -  ECOG Performance status 0 or 1\n\n          -  For Part I only patients chemo-na\u00efve will be included (only adjuvant gemcitabine\n             received in a period earlier than six months will be allowed). For Part II patients\n             who have progressed to gemcitabine in a period shorter than six months can also be\n             included.\n\n          -  Adequate baseline organ function (hematologic, liver, renal and nutritional)\n\n        Exclusion Criteria:\n\n          -  Active infection or other serious illness or autoimmune disease\n\n          -  Treatment with live attenuated vaccines in the last three weeks\n\n          -  Known chronic liver disease (liver cirrhosis, chronic hepatitis)\n\n          -  Treatment with another investigational agent within its five half-lives prior to\n             VCN-01 infusion\n\n          -  Viral syndrome diagnosed during the two weeks before inclusion\n\n          -  Chronic immunosuppressive therapy\n\n          -  Known concurrent malignant hematologic or solid disease\n\n          -  Pregnancy or lactation. Patients must agree to use effective contraception or be\n             surgically sterile.\n\n          -  Patients receiving full-dose anticoagulant / antiplatelet therapy\n\n          -  Patients with Li Fraumeni syndrome or with previous known retinoblastoma protein\n             pathway germinal deficiency"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02045589", 
            "org_study_id": "P-VCNA-002", 
            "secondary_id": "2012-005556-42"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part I: Dose Escalation, Combination", 
                    "Part II: VCN-01, Single Agent"
                ], 
                "description": "Genetically modified human adenovirus encoding human PH20 hyaluronidase", 
                "intervention_name": "VCN-01", 
                "intervention_type": "Genetic"
            }, 
            {
                "arm_group_label": "Part I: Dose Escalation, Combination", 
                "description": "1000 mg/m2 intravenous administration", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Gemcitabine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cancer", 
            "Pancreatic adenocarcinoma", 
            "Locally advanced", 
            "Metastatic", 
            "Gemcitabine", 
            "Oncolytic virus"
        ], 
        "lastchanged_date": "January 28, 2014", 
        "location": [
            {
                "contact": {
                    "email": "ramonsalazar@iconcologia.net", 
                    "last_name": "Ramon Salazar, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "L'Hospitalet de Llobregat, Barcelona", 
                        "country": "Spain", 
                        "zip": "08908"
                    }, 
                    "name": "Institut Catal\u00e0 d'Oncologia"
                }, 
                "investigator": {
                    "last_name": "Ramon Salazar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mhidalgo@cnio.es", 
                    "last_name": "Manuel Hidalgo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "25080"
                    }, 
                    "name": "Centro Integral Oncol\u00f3gico Clara Campal"
                }, 
                "investigator": {
                    "last_name": "Manuel Hidalgo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Multicenter, Open-label, Dose Escalation Study of Intratumoral Injections of VCN-01 Oncolytic Adenovirus With or Without Intravenous Gemcitabine in Advanced Pancreatic Cancer.", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety and Tolerability by means of Adverse Events (AEs) and laboratory data", 
                "safety_issue": "Yes", 
                "time_frame": "At least 6 months"
            }, 
            {
                "measure": "Recommended Phase 2 Dose (RP2D) of VCN-01 in combination with Gemcitabine by determination of highest feasible dose (MFD) and any Dose Limiting Toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "At least 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02045589"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Determination of VCN-01 half-life by analyzing viral genome copies in blood", 
                "measure": "Viral Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "48 h"
            }, 
            {
                "description": "At least up to 6 months follow-up in patients at the Maximum Tolerated Dose (MTD)", 
                "measure": "Viral Shedding", 
                "safety_issue": "No", 
                "time_frame": "Up to day 71"
            }, 
            {
                "description": "At least up to 6 months follow-up in patients at the MTD", 
                "measure": "Neutralizing antibodies anti-VCN-01", 
                "safety_issue": "No", 
                "time_frame": "30 days after end of treatment phase"
            }, 
            {
                "measure": "Preliminary anti-tumor activity by Overall Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "CT or MRI scans every 8 weeks until disease progression"
            }, 
            {
                "measure": "Preliminary anti-tumor activity by Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "CT or MRI scans every 8 weeks until disease progression"
            }
        ], 
        "source": "VCN Biosciences, S.L.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "VCN Biosciences, S.L.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}